Aromatase Inhibitors Reduce the Expression of a Hypoxia Metagene in Oestrogen Receptor Positive Breast Cancer in Postmenopausal Women.

被引：0
|
作者：
Ghazoui, Z.
Buffa, F. M.
Dunbier, A. K.
Anderson, H.
Dexter, T.
Smith, I. E.
Harris, A. L.
Dowsett, M.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Breakthrough Breast Canc Res Ctr, London, England
[3] John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：518S / 518S
页数：1
相关论文
共 50 条
  • [1] The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer
    Benson, JR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6807 - 6809
  • [2] Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors
    Clunie, G. P.
    Clark, A.
    Mortimer, C. J.
    Stephenson, S.
    Aitken, J.
    Smith, C.
    Sherwin, E.
    Archer, T. J.
    EJSO, 2009, 35 (05): : 475 - 480
  • [3] Aromatase inhibitors for breast cancer in postmenopausal women
    Campos, SM
    ONCOLOGIST, 2004, 9 (02): : 126 - 136
  • [4] Osteoporosis treatment and 10 years' oestrogen receptor plus breast cancer outcome in postmenopausal women treated with aromatase inhibitors
    Bouvard, B.
    Chatelais, J.
    Soulie, P.
    Hoppe, E.
    Saulnier, P.
    Capitain, O.
    Mege, M.
    Mesgouez-Nebout, N.
    Jadaud, E.
    Abadie-Lacourtoisie, S.
    Campone, M.
    Legrand, E.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 87 - 94
  • [5] POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER: BALANCING BENEFIT AND TOXICITY FROM AROMATASE INHIBITORS
    Ingle, J.
    BREAST, 2013, 22 : S19 - S19
  • [6] Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors
    Ingle, James N.
    BREAST, 2013, 22 : S180 - S183
  • [7] Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer
    Dizdar, Omer
    Bulut, Nilufer
    Altundag, Kadri
    BREAST, 2008, 17 (02): : 120 - 120
  • [8] MANAGEMENT OF AROMATASE INHIBITORS-INDUCED BONE LOSS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE BREAST CANCER
    Karalilova, R.
    Batalov, A.
    Batalov, Z.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S381 - S381
  • [9] The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 16 - 27
  • [10] Cost-effectiveness of aromatase inhibitors versus selective estrogen-receptor modulators for breast cancer prevention in postmenopausal women.
    Groom, Amy Grace
    Skedgel, Chris
    Rayson, Daniel
    Younis, Tallal
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345